Zanidatamab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: Biliary Tract Cancer [accelerated] (label: previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer), Gastric Cancer

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Also in development:Non-Small Cell Lung Cancer · Phase 2HER2-Positive Breast Cancer · Phase 3

Also approved (3)
US
  • Gastroesophageal Adenocarcinoma (GEA) • ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, is indicated for the first-line treatment of adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test [see Dosage and Administration ( 2.1 )] . • ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with HER2-pos
Product first approved 2024Outside this platform's coverageFDA label
EU
  • Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2).
Product first approved 2025EMA
CN
  • Conditional approval: previously treated, unresectable or metastatic HER2-positive (HER2+) biliary tract cancer
Product first approved 2025sec.gov

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (6)
Biliary Tract Cancer
NCT07745296 · UNICANCER
2027-01-02 – 2033-07-02 · Biliary Tract Cancer (BTC)
What this study did
NCT06282575 · Jazz Pharmaceuticals
2024-07-19 – 2030-04-01 · Biliary Tract Cancer
What this study did
HER2-Positive Breast Cancer
Other / comorbidity
NCT05615818 · UNICANCER
2024-07-18 – 2028-06 · Biliary Tract Neoplasms
What this study did
NCT04164199 · BeOne Medicines
2019-12-19 – 2026-05-23 · Advanced Malignancies
What this study did
Phase 2 (19)
Biliary Tract Cancer
NCT07841873 · Anhui Provincial Hospital
2026-11-30 – 2030-12-31 · Biliary Tract Cancer
What this study did
NCT03929666 · Jazz Pharmaceuticals
2019-08-22 – 2025-08-30 · HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
What this study did
Gastric Cancer
NCT07176312 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2026-01-16 – 2029-03 · Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer, PDL-1, Metastases
What this study did
NCT07685704 · Zhifeng Zhao, PhD
2026-07 – 2028-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
What this study did
HER2-Positive Breast Cancer
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07102381 · Jazz Pharmaceuticals
2025-09-24 – 2030-05-02 · HER2-positive Breast Cancer, Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07192068 · UNICANCER
2025-10-30 – 2030-06-24 · Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer, Colorectal Carcinoma, Endometrial
What this study did
Other / comorbidity
NCT07243938 · Tao Zhang
2026-01-15 – 2031-06-01 · Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC), Neoadjuvant Therapy
What this study did
NCT07631871 · Haihua Yuan
2026-06-15 – 2029-12-31 · Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Cervical Neoplasms, Ovarian Neoplasms
What this study did
NCT07405476 · Emory University
2026-04-07 – 2029-12-18 · Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
What this study did
NCT07296705 · Fujian Medical University Union Hospital
2025-10-25 – 2029-12 · Muscle Invasive Bladder Cancer (MIBC)
What this study did
NCT07273981 · Xijing Hospital
2026-01-01 – 2029-07-31 · Gastric/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05035836 · M.D. Anderson Cancer Center
2021-11-16 – 2028-12-29 · Breast Cancer, HER2-positive
What this study did
NCT07290985 · American Association for Cancer Research
2026-07-20 – 2028-12-01 · Gastroesophageal Adenocarcinoma
What this study did
NCT06043427 · Canadian Cancer Trials Group
2024-04-16 – 2027-07-31 · Gastroesophageal Adenocarcinoma
What this study did
NCT04224272 · Jazz Pharmaceuticals
2020-06-10 – 2025-06-30 · HER2+/HR+ Breast Cancer
What this study did
Phase 1/2 (6)
Gastric Cancer
NCT04276493 · BeiGene
2020-03-23 – 2024-10-31 · Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
HER2-Positive Breast Cancer
NCT05868226 · QuantumLeap Healthcare Collaborative
2023-02-15 – 2031-12-30 · HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
What this study did
Other / comorbidity
NCT07477444 · Universitaire Ziekenhuizen KU Leuven
2026-06-01 – 2033-06 · Gastroesophageal Cancer
What this study did
NCT06324357 · Boehringer Ingelheim
2024-06-28 – 2029-01-08 · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
What this study did
NCT07494448 · MedSIR
2026-07-01 – 2028-05-31 · HER 2 Positive Advanced Breast Cancer, Breast Cancer
What this study did
NCT05027139 · Jazz Pharmaceuticals
2021-09-15 – 2025-09-30 · HER2-expressing Cancers
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT07899801 · M.D. Anderson Cancer Center
2027-04-01 – 2030-12-07 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT02892123 · Jazz Pharmaceuticals
2016-09-30 – 2024-10-31 · HER2-expressing Cancers
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1/2 (1)
HER2-Positive Breast Cancer
NCT06253871 · Iambic Therapeutics, Inc
2024-03-25 – 2028-12 · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Biliary Tract Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zanidatamab: this drugApprovedMultispecific antibodyHER2Weak signal
NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023)
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6)
Futibatinib (Lytgobi)Phase 3Small moleculeFGFR (FGFR1/2/3/4)not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
TovecimigPhase 2/3Multispecific antibodyDLL4 x VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
RamucirumabPhase 2Monoclonal antibodyVEGFR2not yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zanidatamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06043427 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06695845 · CT.gov ↗
What to watch
2027 (4)
June 2027 (1)
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2Muscle Invasive Bladder Cancer (MIBC)Recruiting
Est. primary completion 2027-12 · NCT07296705 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-29 · NCT07102381 · CT.gov ↗
What to watch
Phase 1/2HER 2 Positive Advanced Breast Cancer, Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07494448 · CT.gov ↗
What to watch
2028 (12)
March 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-13 · NCT07192068 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-04-28 · NCT06435429 · CT.gov ↗
What to watch
June 2028 (5)
Phase 1/2Gastroesophageal CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07477444 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07685704 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT07290985 · CT.gov ↗
What to watch
Phase 2Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06-30 · NCT07273981 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07841873 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma …Not yet recruiting
Est. primary completion 2028-07-30 · NCT07243938 · CT.gov ↗
What to watch
December 2028 (4)
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-12-01 · NCT06282575 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-07 · NCT07899801 · CT.gov ↗
What to watch
Phase 2Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8 …Recruiting
Est. primary completion 2028-12-18 · NCT07405476 · CT.gov ↗
What to watch
Phase 2Breast Cancer, HER2-positiveRecruiting
Est. primary completion 2028-12-29 · NCT05035836 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 1/2Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma …Recruiting
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2029-03 · NCT07176312 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic Neoplasms …Not yet recruiting
Est. primary completion 2029-12-31 · NCT07631871 · CT.gov ↗
What to watch
2030 (2)
December 2030 (2)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-12-30 · NCT05868226 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
Phase 3Biliary Tract CancerNot yet recruiting
Est. primary completion 2033-07-02 · NCT07745296 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 August 2026Topline resultPhase 3 HERIZON-GEA-01 second interim analysis: ZIIHERA plus chemotherapy improved overall survival versus trastuzumab plus chemotherapy
25 August 2026ApprovalFDA approves Ziihera regimens in first-line HER2+ gastroesophageal adenocarcinoma
US, FDA · Source ↗
25 August 2026FDA action datePDUFA target date August 25, 2026
US, FDA · Source ↗
August 2026ApprovalFDA updates Boxed Warning on Zanidatamab (BLA761416)
US, FDA · FDA · Source ↗
27 April 2026Filing acceptedFDA accepts Ziihera sBLA for first-line HER2+ GEA
US, FDA · Source ↗
27 April 2026Priority reviewFDA grants Priority Review to Ziihera sBLA
US, FDA · Source ↗
1 July 2025ApprovalEC conditional marketing authorization for Ziihera in HER2-positive BTC
EU, EC · Source ↗
30 May 2025ApprovalNMPA conditionally approves zanidatamab in China for HER2+ BTC
CN, NMPA · Source ↗